Search

Displaying results 1701 - 1710 of 9325 in total
  1. Drug

    Lumiracoxib

    go.drugbank.com/drugs/DB01283
    ApprovedWithdrawn

    On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver … New Zealand and Canada have also followed suit in recalling the drug.

  2. Drug

    Leuprolide

    go.drugbank.com/drugs/DB00007
    ApprovedInvestigational

    Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three … [A203222] As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels.

    Products: TOZ ICEREN SIRINGA VE COZUCU ICEREN SIRINGA, 1 ADET, TOZ ICEREN SIRINGA VE COZUCU ICEREN SIRINGA, 1 ADET
  3. Drug

    Fosfomycin

    go.drugbank.com/drugs/DB00828
    ApprovedInvestigational

    [A229338,A230348] It may also be produced synthetically and is commercially available as the disodium salt for intravenous administration and as the calcium or trometamol salt for oral administration. … [A230348] As such there is great interest in exploring the usefulness of fosfomycin for indications beyond the treatment of UTIs.[A230353,A230358]

  4. Drug

    Ceftriaxone

    go.drugbank.com/drugs/DB01212
    ApprovedInvestigational

    the convenience of daily or twice-daily dosing. … [A215582] It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges[A215582], eyes[A215647], and inner ear[A215627].

    Products: NOVOSEF 1 G/10 ML IV ENJEKSİYONLUK TOZ VE ÇÖZÜCÜ, 1 ADET, NOVOSEF 1 G/3,5 ML IM ENJEKSİYONLUK TOZ VE ÇÖZÜCÜ, 1 ADET
  5. Drug

    Insulin aspart

    go.drugbank.com/drugs/DB01306
    ApprovedInvestigational

    to produce or synthesize the insulin needed to manage circulating blood sugar levels. … Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle.

  6. Drug

    Methsuximide

    go.drugbank.com/drugs/DB05246
    Approved

    It is sold by Pfizer under the name Petinutin.

  7. Drug

    Volanesorsen

    go.drugbank.com/drugs/DB15067
    Approved

    [L16621] Volanesorsen was granted a conditional approval by the European Medicines Agency.[L16621] … Volanesorsen is an antisense oligonucleotide that binds to apoC-III mRNA to prevent its translation.

  8. Drug

    Donislecel

    go.drugbank.com/drugs/DB17961
    Approved

    [L47166,L47196] The primary mechanism of action of donislecel is attributed to the secretion of insulin and other pancreatic hormones from infused allogeneic islet cells to mimic endogenous glucose control … [L47196] Donislecel is particularly beneficial for type 1 diabetic patients with hypoglycemia unawareness, the inability to detect blood glucose dropping and thus unable to prevent further hypoglycemia

  9. Drug

    Naldemedine

    go.drugbank.com/drugs/DB11691
    ApprovedInvestigational

    Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opioid-induced Constipation. … It is a modified form of [DB00704] to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier.

  10. Drug

    Alosetron

    go.drugbank.com/drugs/DB00969
    ApprovedWithdrawn

    In June 2002, the FDA approved a supplemental new drug application allowing the remarketing of the drug under restricted conditions of use. … Alosetron was voluntarily withdrawn from the US market in November 2000 by the manufacturer due to numerous reports of severe adverse effects including ischemic colitis, severely obstructed or ruptured